*Note, if Continuing Review is combined with another type of submission, refer to the guide for that type of submission in addition to this template.*

1. Any new information that could affect the ethics, regulations or guidance. (e.g. if this is a placebo-controlled study and a new treatment has been approved, consider whether the inclusion of placebo control remains ethical.)
2. Determine whether the consent form needs to be revised to include new information or to increase understandability.
3. Determine whether the criteria for approval continue to be met.
4. Make one of the following determinations:
	1. Approved
	2. Approved with administrative comments
	3. Modifications required
	4. Deferred
	5. Disapprove
5. List administrative comments, conditions, modifications required or reasons for deferral.
6. Document the recommended approval period. (See [HRP-319 Approval Period](http://research.ucdavis.edu/wp-content/uploads/HRP-319-WORKSHEET-Approval-Period-012017.docx))
7. Document risk level

**Sample Review**

There is/is not any new information that has an effect on this review. The new information is \_\_\_\_\_\_\_\_.

The criteria for approval continue to be/are no longer met. They are not met because \_\_\_\_\_.

I recommend approval/approval with administrative comments/modifications required/deferral.

List administrative comments and/or conditions/modifications required/reasons for deferral.

Approval Period \_\_\_\_\_\_\_\_\_\_\_\_\_\_

Risk Level: \_\_\_\_\_\_\_\_\_\_\_\_\_\_.

The following issues need to be addressed: